Select Language
Integrin alpha 4 beta 7
Integrin alpha 4 beta 7 Overview
| English Name | Integrin alpha-4/beta-7 | Approved Drugs | 4 |
| Drugs in Clinical Trials | 14 | Target Synonym | LPAM-1，Lymphocyte Peyer's patch Adhesion Molecule 1 |
| Highest Development Stage | Approved | ||
| English Name | Integrin alpha-4/beta-7 |
| Target Synonym | LPAM-1，Lymphocyte Peyer's patch Adhesion Molecule 1 |
| Approved Drugs | 4 |
| Drugs in Clinical Trials | 14 |
| Highest Development Stage | Approved |
Integrin alpha 4 beta 7 Product List
- Product Category
Protein (4)Kits (2)Cell (1)
- Product Status
Launched (7)
- Species
Human (5)Cynomolgus (2)
- Tag
His Tag (2)- (3)His Tag & Avi Tag (2)
- Conjugate
Unconjugated (2)- (3)Biotin-labeled (2)
Total: 7
- 1
Integrin alpha 4 beta 7 Background
Integrin alpha 4 beta 7 is an integrin family adhesion receptor that shares subunits with alpha 4 beta 1 (VLA4) and the E-Cadherin receptor, alpha E beta 7 . Integrin alpha 4 beta 7, which is critical for homing to intestinal mucosa, is induced during T cell activation in Peyer’s patches or mesenteric lymph nodes.Its expression requires signals from local dendritic and stromal cells, including secreted retinoic acid. The HIV-1 envelope protein gp120 binds to the active form of Integrin alpha 4 beta 7, and this may or may not account for the concentration of HIV-1 virus in the gut-associated lymphoid tissue (GALT). Integrin alpha 4 beta 7 may also be involved in lymphocyte trafficking in acute intestinal graft vs. host disease (GVHD).
Integrin alpha 4 beta 7 Synonyms
Integrin alpha 4 beta 7,ITGA4&ITGB7
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Etrolizumab | PRO-145223; rhuMAb-Beta7; R-7413; RG-7413 | Phase 3 Clinical | Genentech Inc | Colitis, Ulcerative; Crohn Disease | Details |
| Vedolizumab biosimilar (Polpharma Biologics) | PB-016 | Phase 3 Clinical | Polpharma Biologics Sa | Colitis, Ulcerative; Crohn Disease; Pouchitis | Details |
| Vedolizumab Biosimilar (Intas Pharmaceuticals) | INTP-53; INTP53 | Phase 3 Clinical | Intas Pharmaceuticals Ltd | Colitis, Ulcerative | Details |
| Natalizumab biosimilar (GENERIUM Pharmaceuticals) | GNR-093 | Phase 3 Clinical | Generium Pharmaceuticals | Multiple Sclerosis | Details |
| LY-4268989 | MORF-057; LY-4268989; LY4268989 | Phase 2 Clinical | Morphic Therapeutic Inc | Colitis, Ulcerative; Crohn Disease | Details |
| EA-1080 | EA-1080; NSHO-101 | Phase 2 Clinical | Ea Pharma | Colitis, Ulcerative; Crohn Disease; Inflammatory Bowel Diseases | Details |
| PN-10943 | PN-10943-A; PN-10943; PN-943 | Phase 2 Clinical | Protagonist Therapeutics Inc | Colitis, Ulcerative | Details |
| Emvistegrast | GS-1427 | Phase 2 Clinical | Gilead Sciences Sl | Colitis, Ulcerative; Inflammatory Bowel Diseases | Details |
| ABBV-466 | Phase 2 Clinical | Abbvie Inc | Crohn Disease | Details | |
| SPY-001 | SPY001; SPY-001; PR-011; PR011; SPY001-001 | Phase 2 Clinical | Paragon Therapeutics Inc | Colitis; Colitis, Ulcerative; Inflammatory Bowel Diseases | Details |
| Trosunilimab | ABBV-382 | Phase 2 Clinical | Abbvie Inc | Crohn Disease; HIV Infections | Details |
| PTG-100 | PTG-100 | Phase 1 Clinical | Protagonist Therapeutics Inc | Celiac Disease; Colitis, Ulcerative | Details |
| NSHO-102 | NSHO-102 | Phase 1 Clinical | Ensho Therapeutics Inc | Inflammatory Bowel Diseases | Details |
| Vedolizumab biosimilar (Alvotech) | AVT-16; AVT16 | Phase 1 Clinical | Alvotech Swiss Ag | Colitis, Ulcerative; Immune System Diseases | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Carotegrast methyl | AJM-300 | Approved | Ea Pharma, Eisai Co Ltd | Carogra | Japan | Colitis, Ulcerative | Ea Pharma Co Ltd | 2022-03-28 | Colitis, Ulcerative | Details |
| Vedolizumab | MLN-0002; LPD-02; MLN-002; MLN-02; LDP-02 | Approved | Millennium Pharmaceuticals Inc | Entyvio, Entyvio Pen, Kynteles, 安吉优 | United States | Colitis, Ulcerative; Crohn Disease | Takeda Pharmaceuticals USA Inc | 2014-05-20 | Carcinoma, Non-Small-Cell Lung; Celiac Disease; Cholangitis, Sclerosing; Colitis; Colitis, Ulcerative; Crohn Disease; Gastritis; Hematopoietic stem cell transplantation (HSCT); HIV Infections; Inflammatory Bowel Diseases; Melanoma; Neoplasms; Pediatric Crohn's disease; Pediatric ulcerative colitis; Pouchitis; Solid tumours; Urogenital Neoplasms | Details |
| Natalizumab biosimilar (Polpharma Biologics) | PB-006; DST-356A1 | Approved | Polpharma Biologics Sa | Tyruko | United States | Multiple Sclerosis; Crohn Disease | Sandoz Inc | 2023-08-24 | Crohn Disease; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | Details |
| Natalizumab | BG-0002; TY-21.6; AN-10022; BG-00002; AN-100226; BG-0002-E | Approved | Biogen Inc, Perrigo Llc | Tysabri, Antegran, Antegren | United States | Crohn Disease; Multiple Sclerosis | Biogen Idec | 2004-11-23 | Arthritis, Rheumatoid; Crohn Disease; Demyelinating Diseases; Epilepsies, Partial; Graft vs Host Disease; Ischemic Stroke; Multiple Myeloma; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Myositis, Inclusion Body | Details |
- Overview
- Product List
- Marketed Drug Information
- Clinical Drug Information
Share to: